Navigation Links
Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions
Date:5/8/2008

CTOR(R) Patch results in minimal systemic absorption of diclofenac, one of the best selling and most widely used orally administered NSAIDs worldwide."

Acute pain is a common problem, with one in four adult Americans suffering an episode of pain lasting longer than 24 hours.(1)

Efficacy and Tolerability of FLECTOR(R) Patch in the Treatment of Minor Soft Tissue Injury Pain (Abstract #8332/Poster #278)(2)

The efficacy and tolerability of FLECTOR(R) Patch was evaluated in a randomized, double-blind, placebo-controlled, parallel-group trial of 418 patients, aged 18-65 years who rated the minor soft tissue injuries they sustained within seven days of study entry as having a pain intensity of greater than or equal to five on a zero to 10 scale. Patients self-administered FLECTOR(R) Patch every 12 hours to the injury site. The primary study outcome was post-treatment pain, expressed as a proportion of the baseline pain score, which was recorded on a visual analog scale of zero to 10 in a diary, twice-daily for 14 days, or until pain resolution. The secondary study outcomes included end-of-treatment Investigator Global Assessment of Response to Therapy (a five-point scale, "none" to "excellent"), and time to pain resolution (four scores less than or equal to two).

Patients treated with FLECTOR(R) Patch experienced improved mean pain scores (40.4 percent of baseline score) versus patients using placebo patch (47.4 percent, p<0.05); overall pain reduction was 14.8 percent. FLECTOR(R) Patch patients also reached pain resolution three days sooner than those in the placebo patch group (median, 10.0 versus 13.5 days, p=0.01). Additionally, at the conclusion of the study, the Investigator Global Assessment of Response to Therapy significantly favored the FLECTOR(R) Patch: patient response to treatment was rated "good" to "excellent" for 57.8 percent of FLECTOR(R) Patch patients, versus 48.4 percent of placebo patch patients, and a "no"/"poor" response w
'/>"/>

SOURCE Alpharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
2. Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology
3. Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
4. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
5. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
6. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
9. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/13/2008)...wswire-USNewswire/ -- In women at increased,risk f...amination to,routine mammography revealed 28 perce...he additional ultrasound exam substantially increa...essary biopsies, according to an,American College ...ed in,the May 14, 2008 issue of the Journal of Ame...
(Date:5/13/2008)... /- Gene therapy to replace the,fault...ase that is fatal by,age 8-12 years, was able to s...n treated children, according to a paper published... 19 No. 5) of Human Gene Therapy, a,peer-reviewed ...per is,available free online at http://www.lieber...
(Date:5/13/2008)...cular tumor grade and endocrine benefit offer ...come-, SAN DIEGO, May 13 /- AviaraDx...le describing the discovery, development and,valid... (Molecular Grade,Index), that improves the accura...on of distant disease recurrence. The authors also...
(Date:5/13/2008)...w Approach for the Treatment of Inflammatory ...ers $10 Million Payment from Partner GlaxoSmithKli... ChemoCentryx, Inc., today,announced the initiatio...-available, novel small molecule compound designed...r which is associated with inflammatory,diseases s...
Breaking Medicine Technology:Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer 2Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer 3Gene Therapy Slows Progression of Fatal Neurodegenerative Disease in Children 2AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients 2AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients 3AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients 4ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 2ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 3ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 4ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 5Smithsonian identifies invasive crab species in Panama Canal expansion area 459 1Smithsonian identifies invasive crab species in Panama Canal expansion area 459 2International Watchdog Group Singles Out Resurrection for Anti Union Violations 1606 1International Watchdog Group Singles Out Resurrection for Anti Union Violations 1606 2Countering Colds With Common Sense 1603 1Countering Colds With Common Sense 1603 2Countering Colds With Common Sense 1603 3VIDEO from Medialink and Siemens 3A The Next Generation Allergy Test Nothing to Sneeze At 1600 1
...)--Mar 7, 2007 - BioLineRx Ltd.,(TASE:BLRX), Israe...ay pre-clinical data from trials of BL-1040 demons...terioration of the myocardium,after a myocardial i...latation and eventual heart failure in a pig model...feld Cardiac Research,Institute at Sheba Medical C...
...olled Study in Inoperable Chronic,Thromboembolic P...ion in Pulmonary Vascular Resistance Met - Six-Min...spnoea Score and,Biological Disease Marker , , A... (SWX:,ATLN) announced today the initial results f...ter study BENEFiT (Bosentan Effects in,Inoperable ...
Other Medicine Technology:BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 2BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 3Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 2Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 3Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 4Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 5Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 6
(Date:5/13/2008)... Temperature Stable Treatment for Hemophilia With ...ence to Patients, PRINCETON, N.J., May 13 /PRNews...at the US Food and Drug Administration (FDA) has a...Recombinant] Room Temperature,Stable), the first r...le,for the treatment of bleeding episodes in patie...
(Date:5/13/2008)... on electronic bingo to fulfill the unmet needs of...mmunities, SACRAMENTO, Calif., May 13 /PRNewswire...nnounced its formation to advocate for the use of,...bingo as a responsible,legal and consistent fundi...zations for this new alliance include Disabled Spo...
(Date:5/13/2008)...ration Among 52 Companies Recognized for Promoting...LE GROVE, Minn., May 13 /PRNewswire/ -- The Nation... organization of large employers, today,honored Da...t and,dedication to promoting a healthy workplace ...ees and families., (Logo: http://www.newscom.com...
(Date:5/13/2008)... rental revenue increase 12.0 percent demonstratin...l-Rom reporting for first time since separation; s...owing results, - Management updates financial guid... and operational momentum, BATESVILLE,...oldings,Inc. (NYSE: HRC ), reporting for the fir...
Breaking Medicine News(10 mins):Health News:FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors 2Health News:FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors 3Health News:FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors 4Health News:Charities Form Alliance to Preserve and Improve Charity Bingo 2Health News:National Business Group on Health Honors Data Recognition Corporation as One of Best Employers for Healthy Lifestyles 2Health News:National Business Group on Health Honors Data Recognition Corporation as One of Best Employers for Healthy Lifestyles 3Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 2Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 3Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 4Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 5Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 6Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 7Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 8Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 9Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 10Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 11Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 12Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 13Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 14
...lt hair follicles undergo a growth cycle consistin...en), and rest (telogen). Researchers demonstrated ...en-phase adult hair follicles is sufficient to ini... that the transient activation of a protein called...
...hma is one of the most common chronic conditions a...dy shows children who have multiple ear // infecti...osed with asthma. The study included 7,538 childre...te medical history for each child was reviewed, as...
... all vitamins may be good for you. A new study sho...ease, antioxidant vitamins, such as // E, C and be...bad” form of cholesterol. Some studies have shown ...of the lipoprotein-breakdown pathway in rat and mo...
...imates show white children under age 2 who were sp... risk of behavior problems that // required a pare...to children who were not spanked. However, the lin...s in black and Hispanic children was not significa...
Other Medicine News:Health News:New Hair in 15 Days Could Now Be A Possibility Say Researchers 2
...stem delivers an unmatched combination of speed, a...tion for assessing and monitoring a patient's A1C ...ires only a simple fingerstick and delivers A1C re...en and time-tested having received full NGSP certi...
Metrika's A1cNow Monitor is the first ever single-use test for hemoglobin A1c, it is the "gold standard" indicator of diabetes management. The test is easy to use, needs only a drop of blood and take
The sole coagulation analyzer in the world that uses a unique dry reagent card.
...fully automated, benchtop coagulation workstation ...munological assays in true random access fashion. ...fers high throughput and rapid processing of STAT ...ing. All sample and calibrator dilutions are perfo...
Medicine Products: